1h Free Analyst Time
The oligonucleotide therapeutics market is forecasted to grow by USD 13443.7 million during 2023-2028, accelerating at a CAGR of 19.87% during the forecast period. The report on the oligonucleotide therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing incidence of cancer boosts demand for novel diagnostics, need for personalized medicines for neurological disorders, and increasing availability of oligonucleotide therapeutic drugs.
The oligonucleotide therapeutics market is segmented as below:
By Type
- Antisense oligonucleotides
- RNA interference
- Aptamers and others
By Application
- Neurological
- Cancer
- Infectious diseases and others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the oligonucleotide therapeutics market covers the following areas:
- Oligonucleotide therapeutics market sizing
- Oligonucleotide therapeutics market forecast
- Oligonucleotide therapeutics market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Application
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global oligonucleotide therapeutics market: Agilent Technologies Inc., Alnylam Pharmaceuticals Inc., Biogen Inc., CSL Ltd., GlaxoSmithKline Plc, Ionis Pharmaceuticals Inc., Maravai LifeSciences Holdings Inc., Merck KGaA, Nippon Shinyaku Co. Ltd., Novartis AG, Pfizer Inc., Sarepta Therapeutics Inc., and Thermo Fisher Scientific Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is advances in DNA sequencing increasing adoption of microfluidic techniques."
According to the report, one of the major drivers for this market is the increasing incidence of cancer boosts demand for novel diagnostics.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Agilent Technologies Inc.
- Alnylam Pharmaceuticals Inc.
- Biogen Inc.
- CSL Ltd.
- GlaxoSmithKline Plc
- Ionis Pharmaceuticals Inc.
- Maravai LifeSciences Holdings Inc.
- Merck KGaA
- Nippon Shinyaku Co. Ltd.
- Novartis AG
- Pfizer Inc.
- Sarepta Therapeutics Inc.
- Thermo Fisher Scientific Inc.
